How Much Does Zepbound Cost in Alabama in 2026?

Alabama Retail Pricing for Zepbound in 2026

The manufacturer list price set by Eli Lilly for Zepbound is $1,059.87 per four-week supply across all dose strengths. This price holds at Alabama retail pharmacies including CVS, Walgreens, and independent locations throughout Birmingham, Huntsville, Mobile, and Montgomery. Cash-pay patients with no insurance coverage will pay this full amount.

Zepbound received FDA approval in November 2023 for adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. The drug is a dual GIP/GLP-1 receptor agonist, and this dual mechanism separates it from single-target GLP-1 medications like semaglutide. In SURMOUNT-1 (N=2,539), participants on the highest 15 mg dose achieved 22.5% mean body weight reduction at 72 weeks compared to 3.1% with placebo [1]. That magnitude of weight loss was unprecedented for a pharmaceutical intervention in a Phase III trial at the time of publication.

Prices do not vary by dose. Whether a patient fills the 2.5 mg starter pen or the 15 mg maintenance pen, the pharmacy charges the same list price. Patients starting Zepbound should expect to remain on the medication long-term, since weight regain after discontinuation is well documented. The SURMOUNT-1 extension data showed that participants who stopped tirzepatide regained roughly two-thirds of lost weight within one year [1].

Alabama Medicaid Does Not Cover Zepbound

Alabama Medicaid does not include Zepbound on its preferred drug list for chronic weight management. This exclusion affects a significant portion of Alabama residents. According to the Kaiser Family Foundation, Alabama's Medicaid program covered approximately 1.1 million enrollees as of 2025, and the state has not expanded Medicaid under the Affordable Care Act.

The exclusion is not unique to Alabama. Most state Medicaid programs classify anti-obesity medications as optional rather than mandatory benefits under federal Medicaid law. The Treat and Reduce Obesity Act, which would require Medicare Part D coverage of anti-obesity medications, has been introduced repeatedly in Congress but has not yet passed. Alabama Medicaid enrollees seeking tirzepatide for weight management have limited options: they may qualify for compounded tirzepatide at reduced cost, seek manufacturer patient assistance, or pay cash.

For patients with a concurrent type 2 diabetes diagnosis, a different pathway exists. Mounjaro (the same tirzepatide molecule branded for diabetes) may receive Medicaid coverage under Alabama's diabetic formulary. A prescriber can submit a prior authorization for Mounjaro if the patient meets ADA Standards of Care criteria for type 2 diabetes pharmacotherapy [2]. The distinction matters: same drug, different indication, different coverage outcome.

Commercial Insurance Coverage Across Alabama

Commercial insurers in Alabama vary widely in their Zepbound coverage policies. Blue Cross Blue Shield of Alabama, the state's largest commercial insurer, began adding GLP-1 receptor agonists for weight management to select employer-sponsored plans in 2025, but coverage depends on the specific plan purchased by the employer.

Patients with commercial coverage that includes Zepbound can combine it with the Eli Lilly Zepbound Savings Card to reduce out-of-pocket costs to $25 per month for up to 12 fills. The savings card covers up to $563 per fill, which offsets most or all of a typical commercial copay. Patients without any insurance coverage can use a separate Lilly cash-pay program priced at $399 per month for single-dose vials (available since March 2025), though these vials require manual syringe preparation rather than the standard auto-injector pen.

Self-funded employer plans in Alabama have the most flexibility to add or exclude weight management drugs. Large Alabama employers including Regions Financial, Alabama Power, and the University of Alabama Health System set their own formulary inclusions. Patients should call the number on the back of their insurance card and ask specifically: "Is tirzepatide (Zepbound) covered under my pharmacy benefit for the diagnosis code E66.01 (morbid obesity)?"

A few practical steps to confirm coverage status before filling:

1. Request a pharmacy benefit check at the prescribing clinic
2. Ask the pharmacy to run a test claim before processing
3. If denied, request the specific denial reason code for appeal
4. For employer-sponsored plans, ask HR whether anti-obesity medications are a covered benefit class

Compounded Tirzepatide in Alabama: Legal Status and Pricing

Compounded tirzepatide is available in Alabama through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and can compound tirzepatide from bulk pharmaceutical-grade ingredients when a valid patient-specific prescription exists.

Pricing for compounded tirzepatide in Alabama typically ranges from $249 to $450 per month depending on the pharmacy, dose, and dispensing model. That represents a 58% to 76% savings compared to brand-name Zepbound. Several telehealth platforms now connect Alabama patients with prescribers who can write prescriptions filled by out-of-state 503A pharmacies that ship to Alabama addresses.

The legal framework requires clarification. The FDA placed tirzepatide on and then removed it from the drug shortage list in late 2024. Under the Federal Food, Drug, and Cosmetic Act Section 503A, pharmacies can compound copies of commercially available drugs only under certain conditions. Lilly has pursued legal action against some compounders. Patients considering compounded tirzepatide should verify that their pharmacy holds a current Alabama Board of Pharmacy compounding license and uses USP 797-compliant sterile compounding practices.

Potency and sterility testing standards differ between brand-name and compounded products. Brand-name Zepbound undergoes FDA-mandated batch testing. Compounded tirzepatide quality depends on the individual pharmacy's processes. The Endocrine Society published guidance in 2024 recommending that patients discuss risks and benefits of compounded peptides with their prescriber [3].

Eli Lilly Savings Programs for Alabama Patients

Lilly offers three distinct affordability programs, each targeting a different patient population. The programs cannot be combined with each other, and each has its own eligibility criteria.

Zepbound Savings Card (commercial insurance). Eligible patients with commercial insurance pay $25 per month. The card covers up to $563 per fill and is valid for up to 12 fills over 12 months. Government insurance (Medicare, Medicaid, TRICARE) is excluded. No income requirement exists.

LillyDirect Cash-Pay Vials. Patients without insurance can purchase single-dose vials at $399 per month through the LillyDirect platform. These vials ship directly from Lilly-contracted pharmacies and are genuine brand-name tirzepatide. The tradeoff: patients must draw and inject from a vial using a syringe rather than using the KwikPen auto-injector.

Lilly Patient Assistance Program. Uninsured patients earning below 400% of the federal poverty level ($62,400 for an individual in 2026) may qualify for free Zepbound through Lilly's patient assistance program. Approval requires income documentation and prescriber enrollment.

Alabama patients should also check whether their prescriber's office participates in any buy-and-bill arrangements, where the clinic purchases Zepbound at a discounted rate and administers it in-office, billing the patient's medical (not pharmacy) benefit.

Telehealth Prescribing of Zepbound in Alabama

Alabama permits telehealth prescribing of Zepbound. The state requires an initial synchronous audio-video visit to establish the patient-prescriber relationship before a controlled or specialty medication can be prescribed. After the initial visit, follow-up appointments for dose titration and monitoring can occur via telehealth.

The Alabama Board of Medical Examiners requires that prescribers be licensed in Alabama or hold an active interstate compact license that covers the state. National telehealth platforms operating in Alabama must employ or contract with Alabama-licensed prescribers. Several platforms offer complete weight management programs that include prescriber visits, lab monitoring, and Zepbound prescriptions for monthly program fees ranging from $99 to $199 (medication cost separate).

For Zepbound specifically, the prescriber should verify BMI criteria at baseline, order baseline labs (fasting glucose, HbA1c, lipid panel, hepatic function, and thyroid function), and schedule dose titration check-ins every four weeks during the escalation phase from 2.5 mg through the target maintenance dose [4].

Dose Titration Schedule and Total Cost Projection

Zepbound follows a fixed titration schedule with five dose levels. Each dose is maintained for four weeks before escalation. Not every patient reaches the maximum 15 mg dose. Some achieve clinically meaningful weight loss (≥5% body weight) at 5 mg or 10 mg and remain there.

The standard titration:

• Weeks 1 to 4: 2.5 mg once weekly (starting dose, not therapeutic)
• Weeks 5 to 8: 5.0 mg once weekly
• Weeks 9 to 12: 7.5 mg once weekly
• Weeks 13 to 16: 10.0 mg once weekly
• Week 17 onward: 15.0 mg once weekly (maximum dose)

At the $1,059 per month list price, a full first year of Zepbound costs $12,708 before any discounts. With the Lilly savings card and commercial insurance, the same year costs $300. Through LillyDirect vials, it totals $4,788. And via compounded tirzepatide at $249 per month, the annual cost is $2,988.

The SURMOUNT-1 trial showed weight loss was dose-dependent: the 5 mg group lost 15.0% of body weight, the 10 mg group lost 19.5%, and the 15 mg group lost 22.5% at 72 weeks [1]. Patients and prescribers must weigh the clinical benefit of higher doses against cost when insurance coverage is limited. A patient who achieves their weight loss goal at 10 mg has no clinical reason to escalate to 15 mg.

How Alabama Compares to Neighboring States

Retail pricing for brand-name Zepbound is uniform across Alabama and its neighbors (Mississippi, Tennessee, Georgia, Florida) because the manufacturer list price does not vary by geography. The differences emerge in coverage policy and compounding access.

Tennessee's Medicaid program (TennCare) also excludes anti-obesity medications. Georgia Medicaid has the same exclusion. Mississippi Medicaid similarly does not cover Zepbound for weight loss. Florida Medicaid does cover certain anti-obesity medications through prior authorization, though tirzepatide approval rates vary by managed care plan [5].

For compounded tirzepatide, all four bordering states permit 503A pharmacy compounding under their respective state pharmacy board regulations. Alabama patients near state borders may find competitive pricing by comparing pharmacies in neighboring states, though the prescription must be written by a provider licensed in the state where the pharmacy is located, or the pharmacy must be licensed to ship into Alabama.

Practical Steps to Get the Lowest Zepbound Price in Alabama

The optimal cost pathway depends on insurance status.

If commercially insured with Zepbound coverage: Use the Lilly savings card. Cost: $25 per month. Call your insurer first, confirm coverage, then activate the savings card at zepbound.lilly.com.

If commercially insured without Zepbound coverage: File a formulary exception request. Include the patient's BMI, comorbidity documentation, and prior weight management attempts. If denied on appeal, pivot to the LillyDirect vial program ($399/month) or compounded tirzepatide ($249 to $450/month).

If uninsured and income below 400% FPL: Apply for the Lilly Patient Assistance Program. This provides free brand-name Zepbound.

If uninsured and above income threshold: Compare LillyDirect vials ($399/month) against compounded tirzepatide ($249 to $450/month). Factor in the clinical visit cost from your telehealth provider.

If on Alabama Medicaid: Zepbound for weight loss is not covered. Ask your prescriber whether a concurrent diagnosis (e.g., type 2 diabetes, where Mounjaro may be covered) creates an alternative formulary path. Otherwise, the Lilly Patient Assistance Program or compounded tirzepatide are the remaining options.

According to the CDC's Behavioral Risk Factor Surveillance System, Alabama's adult obesity prevalence was 39.1% in 2023, the fifth highest in the nation [6]. The gap between clinical need and insurance coverage remains wide. Patients who cannot access Zepbound through any of the pathways above should discuss alternative GLP-1 receptor agonists (liraglutide, semaglutide) with their prescriber, as formulary coverage varies by drug.